EHA 2022 | Integrated genetic diagnostics of patients with early onset de novo MDS
Enrico Attardi
• 10 Jun 2022
Enrico Attardi, MD, University of Rome Tor Vergata, Rome Italy, comments on the results of a study using low-coverage whole-genome sequencing (WGS) on plasma cell-free DNA (cf-DNA) to define the molecular and cytogenetic characteristics of patients with early onset de novo myelodysplastic syndromes (MDS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
